Number of participants experiencing any serious adverse events · Adults (mean study ages 25 to 55 years) with acute postoperative pain after dental, mixed minor, abdominal, or orthopedic surgeries
Intravenous diclofenac showed no clear difference in number of participants experiencing a serious adverse event compared with another NSAID (low certainty).
1 finding from 1 review
Median (mean) time to use of rescue medication · Adults (mean study ages 25 to 55 years) with acute postoperative pain after dental, mixed minor, abdominal, or orthopedic surgeries
1 finding from 1 review
Number of participants using rescue medication over 4 to 6 hours postinterventions · Adults (mean study ages 25 to 55 years) with acute postoperative pain after dental, mixed minor, abdominal, or orthopedic surgeries
Intravenous diclofenac may leads to lower number of participants using rescue medication over 4 to 6 hours… compared with placebo (low certainty).
1 finding from 1 review
Number of participants reporting an adverse event · Adults (mean study ages 25 to 55 years) with acute postoperative pain after dental, mixed minor, abdominal, or orthopedic surgeries
Intravenous diclofenac showed no clear difference in number of participants reporting any adverse event compared with placebo (low certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · Adults (mean study ages 25 to 55 years) with acute postoperative pain after dental, mixed minor, abdominal, or orthopedic surgeries
Intravenous diclofenac showed no clear difference in number of participants experiencing a serious adverse event compared with placebo (low certainty).
1 finding from 1 review
At least 50% reduction in pain · Adults (mean study ages 25 to 55 years) with acute postoperative pain after dental, mixed minor, abdominal, or orthopedic surgeries
2 findings from 1 review
Median (mean) time to use of rescue medication · Adults (mean study ages 25 to 55 years) with acute postoperative pain after dental, mixed minor, abdominal, or orthopedic surgeries
1 finding from 1 review
No nausea or vomiting over trial period · cancer patients
Olanzapine probably leads to higher no nausea or vomiting over trial period compared with placebo/no treatment (moderate certainty).
1 finding from 1 review
RR 1.98 [1.59, 2.47]
Studies not reported
Moderate
Participant satisfaction · cancer patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · cancer patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient Global Impression of Change · cancer patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse events · cancer patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Somnolence/fatigue · cancer patients
It is very uncertain whether olanzapine changes somnolence/fatigue compared with NK1 antagonist (very low certainty).
1 finding from 1 review
RR 1.33 [0.4, 4.49]
Studies not reported
Very low
Serious adverse events · cancer patients
Olanzapine showed no clear difference in serious adverse events compared with placebo/no treatment (low certainty).
1 finding from 1 review
RR 2.46 [0.48, 12.55]
Studies not reported
Low
Participant preference ‐ wish to use drug in next treatment · cancer patients
Olanzapine showed no clear difference in participant preference ‐ wish to use drug in next treatment compared with placebo/no treatment (moderate certainty).
1 finding from 1 review
RR 1.43 [0.97, 2.09]
Studies not reported
Moderate
Quality of life · cancer patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient Global Impression of Change · cancer patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse events · cancer patients
Olanzapine showed no clear difference in other adverse events compared with placebo/no treatment (low certainty).
1 finding from 1 review
RR 1.71 [0.99, 2.96]
Studies not reported
Low
Somnolence/fatigue · cancer patients
Olanzapine probably leads to higher somnolence/fatigue compared with placebo/no treatment (moderate certainty).
1 finding from 1 review
RR 2.33 [1.3, 4.18]
Studies not reported
Moderate
No nausea or vomiting over trial period · cancer patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found